Answers are grounded in this paper and cite their sources.
2] We report a case in which a PD-1 blocking antibody was administered to a patient with refractory diffuse large B-cell lymphoma (DLBCL) and progressive lymphoma after therapy with CAR-modified T cells directed against CD19 (CART19). Following PD-1 blockade, the patient had a clinically significant antitumor response, an expansion of CART19 cells, and decreased coexpression of PD-1 and Eomes by CART19 cells. This case suggests that PD-1 blockade can be effective against cancers failing to respond to CAR-modified T-cell therapy.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: